특발성 폐 섬유증 및 간질성 폐 질환 예상 결과 레지스트리 (IPF/ILD-PRO)
특발성 폐 섬유증 예상 결과(IPF-PRO) 및 진행성 표현형 예상 결과가 있는 만성 섬유화 간질 폐 질환(IPF-PRO/ILD-PRO) 레지스트리
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.
연구 개요
상태
상태
정황
정황
상세 설명
This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Rosalia Blanco
- 전화번호: 919-660-0890
- 이메일: rosalia.blanco@duke.edu
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35294
- 모병
- University of Alabama - Birmingham
-
수석 연구원:
- Tejaswini Kulkarni, MD
-
연락하다:
- Arnissa Hopson
- 전화번호: 205-934-1657
- 이메일: agoggins@uabmc.edu
-
-
Arizona
-
Tucson, Arizona, 미국, 85721
- 모병
- University of Arizona
-
수석 연구원:
- Sally A Suliman, MD
-
연락하다:
- Daniel Castaneda-Beltran
- 전화번호: 602-827-2347
- 이메일: dcastanedabeltra@arizona.edu
-
-
California
-
Los Angeles, California, 미국, 90033
- 모병
- University of Southern California
-
연락하다:
- Lynn Fukusima
- 이메일: Lynn.Fukushima@med.usc.edu
-
수석 연구원:
- Toby Maher, MD
-
Los Angeles, California, 미국, 90024
- 모병
- University of California - Los Angeles
-
수석 연구원:
- John Belperio, MD
-
연락하다:
- Stephanie Roblero
- 전화번호: 310-627-2319
- 이메일: sroblero@mednet.ucla.edu
-
Stanford, California, 미국, 94305
- 모병
- Stanford University
-
수석 연구원:
- Rishi Raj, MD
-
연락하다:
- Summer Zhu
- 전화번호: 650-724-5424
- 이메일: szhuye@stanford.edu
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- University of Colorado
-
수석 연구원:
- Joyce Lee, MD
-
연락하다:
- Olivia Brohl
- 전화번호: 303-724-0641
- 이메일: Olivia.brohl@cuanschutz.edu
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06520
- 모병
- Yale University
-
수석 연구원:
- Mridu Gulati, MD
-
연락하다:
- Maksym Minasyan
- 전화번호: 203-785-4177
- 이메일: maksym.minasyan@yale.edu
-
-
Florida
-
Gainesville, Florida, 미국, 32610-3175
- 모병
- University of Florida
-
연락하다:
- Lisbetty Lugo
- 이메일: lisbetty.lugo@medicine.ufl.edu
-
수석 연구원:
- Diana Gomez Manjarres, MD
-
Tampa, Florida, 미국, 33606
- 모병
- University of South Florida
-
수석 연구원:
- Jose D Herazo-Maya, MD
-
연락하다:
- Natasha Brown
- 이메일: nbrown@tgh.org
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- 모병
- Emory University
-
연락하다:
- Tracy Halabi
- 전화번호: 404-712-7458
- 이메일: tracy.halaby@emory.edu
-
수석 연구원:
- Srihari Veeraraghavan, MD
-
Austell, Georgia, 미국, 30106
- 모병
- Piedmont Healthcare
-
수석 연구원:
- Amy Case, MD
-
연락하다:
- Munachi (Muna) Iwotor
- 전화번호: 404-291-9062
- 이메일: munachi.iwotor@piedmont.org
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- 모병
- University of Chicago
-
수석 연구원:
- Mary Strek, MD
-
연락하다:
- Vanita Patel
- 이메일: vpatel4@bsd.uchicago.edu
-
Evanston, Illinois, 미국, 60611
- 모병
- Northwestern University
-
연락하다:
- Phillip Cooper
- 전화번호: 312-503-0406
- 이메일: p-cooper@northwestern.edu
-
수석 연구원:
- Bradford Bemiss, MD
-
Maywood, Illinois, 미국, 60153
- 모병
- Loyola University Health System
-
수석 연구원:
- Daniel Dilling, MD
-
연락하다:
- Sloan White
- 이메일: swhite29@luc.edu
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- 종료됨
- University of Kansas
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40536
- 모병
- University of Kentucky
-
수석 연구원:
- Girish Nair, MD
-
연락하다:
- Kai Su
- 전화번호: 859-257-4501
- 이메일: kai.su@uky.edu
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70112
- 모병
- Tulane University
-
수석 연구원:
- Joe Lasky, MD
-
연락하다:
- Sandy Ditta
- 전화번호: 504-988-4040
- 이메일: sditta@tulane.edu
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모집하지 않고 적극적으로
- University of Michigan
-
Detroit, Michigan, 미국, 48202
- 모병
- Henry Ford Health
-
연락하다:
- Deepti Naidu
- 전화번호: 313-916-8732
- 이메일: dnaidu1@HFHS.ORG
-
수석 연구원:
- Asif Abdul Hameed, MD
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55455
- 모병
- University of Minnesota
-
연락하다:
- Mandi DeGrote
- 전화번호: 612-626-7609
- 이메일: carl1032@umn.edu
-
수석 연구원:
- Hyum Kim, MD
-
-
Mississippi
-
Jackson, Mississippi, 미국, 39216
- 모병
- University of Mississippi Medical Center
-
수석 연구원:
- Kimberly Dobbs, MD
-
연락하다:
- Leadeashia Brackett
- 전화번호: 601-496-7814
- 이메일: lbrackett@umc.edu
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- 모병
- Washington University
-
수석 연구원:
- Tonya Russell, MD
-
연락하다:
- Mona Noroozi
- 전화번호: 314-362-3705
- 이메일: mnoroozi@wustl.edu
-
-
New York
-
New York, New York, 미국, 10065
- 모병
- Weill Medical College of Cornell University
-
수석 연구원:
- Kerri Aronson, MD
-
연락하다:
- Alicia Morris
- 전화번호: 646-692-2741
- 이메일: ajm2017@med.cornell.edu
-
New York, New York, 미국, 10016
- 모집하지 않고 적극적으로
- NYU Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27514
- 모병
- UNC Chapel Hill
-
수석 연구원:
- Jason Lobo, MD
-
연락하다:
- Jackson Pettee
- 이메일: Jackson_pettee@med.unc.edu
-
Durham, North Carolina, 미국, 27705
- 모병
- Duke University
-
수석 연구원:
- Lake Morrison, MD
-
연락하다:
- Lauren Gray
- 전화번호: 919-684-7317
- 이메일: lauren.gray@duke.edu
-
Greensboro, North Carolina, 미국, 27403
- 모병
- Pulmonix LLC
-
수석 연구원:
- Murali Ramaswamy, MD
-
연락하다:
- Mei Zheng
- 전화번호: 336-522-8870
- 이메일: mei.zheng@pulmonix.com
-
Wilmington, North Carolina, 미국, 28401
- 종료됨
- PMG Research
-
Winston-Salem, North Carolina, 미국, 27157
- 모병
- Wake Forest Baptist Health
-
연락하다:
- Bob Hmieleski
- 전화번호: 336-713-8550
- 이메일: bhmieles@wakehealth.edu
-
수석 연구원:
- Andrew Namen, MD
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45267
- 모집하지 않고 적극적으로
- University of Cincinnati Medical Center
-
Cleveland, Ohio, 미국, 44195
- 모병
- Cleveland Clinic
-
수석 연구원:
- Brian Southern, MD
-
연락하다:
- Ron Wehrmann
- 전화번호: 2164450574
- 이메일: wehrmar@ccf.org
-
Columbus, Ohio, 미국, 43210
- 모병
- The Ohio State University
-
연락하다:
- Benjamin Hood
- 이메일: benjamin.hood2@osumc.edu
-
수석 연구원:
- John Odackal
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- 모병
- University of Oklahoma
-
수석 연구원:
- Jad Kebbe, MD
-
연락하다:
- Maria Mason
- 전화번호: 405-271-6173
- 이메일: maria-l-mason@ouhsc.edu
-
-
Oregon
-
Portland, Oregon, 미국, 97220
- 모병
- Oregon Clinic
-
수석 연구원:
- David Hotchkin, MD
-
연락하다:
- Meg Day
- 전화번호: 503-963-3182
- 이메일: mday@orclinic.com
-
-
Pennsylvania
-
Hershey, Pennsylvania, 미국, 17033
- 모병
- Penn State College of Medicine - Hershey
-
수석 연구원:
- Rebecca Bascom, MD
-
연락하다:
- Tim Sheehan
- 전화번호: 717-531-2925
- 이메일: tsheehan@pennstatehealth.psu.edu
-
Philadelphia, Pennsylvania, 미국, 19140
- 모병
- Temple University
-
수석 연구원:
- Rachel Criner, MD
-
연락하다:
- Luis Cardenas-Osorio
- 전화번호: 215-707-3311
- 이메일: Luis.Cardenas-Osorio@tuhs.temple.edu
-
Philadelphia, Pennsylvania, 미국, 19144
- 모병
- Thomas Jefferson University
-
수석 연구원:
- Ross Summer, MD
-
연락하다:
- Ramya Talluri, BSN, RN
- 이메일: RamyaPriya.Talluri@jefferson.edu
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- 모병
- Medical University of South Carolina
-
수석 연구원:
- Timothy Whelan, MD
-
연락하다:
- Audra Wiser
- 이메일: wisera@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37232
- 모병
- Vanderbilt University
-
연락하다:
- James Del Greco
- 전화번호: 615-343-7068
- 이메일: james.del.greco@vumc.org
-
수석 연구원:
- Justin Hewlett, MD
-
-
Texas
-
Dallas, Texas, 미국, 75235
- 모병
- University of Texas Southwestern
-
수석 연구원:
- John Fitzgerald, MD
-
연락하다:
- Meagan Galvan
- 전화번호: 214-645-6489
- 이메일: Maegan.Galvan@UTSouthwestern.edu
-
Dallas, Texas, 미국, 75246
- 모병
- Baylor University Medical Center at Dallas
-
수석 연구원:
- Yolanda Mageto, MD
-
연락하다:
- Mary Alayo
- 전화번호: 214-820-6276
- 이메일: Mary.Alayo@BSWHealth.org
-
Houston, Texas, 미국, 77030
- 모병
- Baylor College of Medicine
-
수석 연구원:
- Ivan Rosas, MD
-
연락하다:
- Maria C Perea
- 이메일: Maria.Perea@bcm.edu
-
Houston, Texas, 미국, 77030
- 모병
- Houston Methodist Lung Center
-
수석 연구원:
- Zeenat Safdar, MD
-
연락하다:
- Laura Valecillos Loukidis
- 전화번호: 346-238-4637
- 이메일: lvvalecillosloukidis@houstonmethodist.org
-
Houston, Texas, 미국, 77030
- 모병
- The University of Texas Health Science Center At Houston
-
수석 연구원:
- Rodeo Abrencillo, MD
-
연락하다:
- Beverly Rios
- 전화번호: 713-486-6152
- 이메일: Beverly.Rios@uth.tmc.edu
-
-
Utah
-
Salt Lake City, Utah, 미국, 84108
- 모병
- University of Utah
-
연락하다:
- Adeline Langer
- 전화번호: 801-581-5811
- 이메일: adeline.langer@hsc.utah.edu
-
수석 연구원:
- Mary Beth Langer, MD
-
Salt Lake City, Utah, 미국, 84111
- 모병
- Intermountain Health
-
연락하다:
- Aisha Skowyra
- 전화번호: 801-507-2439
- 이메일: Aisha.fairclough@imail.org
-
수석 연구원:
- Erin Blackstock, MD
-
-
Vermont
-
Colchester, Vermont, 미국, 05446
- 모집하지 않고 적극적으로
- University of Vermont Lung Center
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22908
- 모집하지 않고 적극적으로
- University from Virginia
-
Falls Church, Virginia, 미국, 22042-3307
- 모병
- Inova Health Care Services
-
연락하다:
- Taruni Maganti
- 전화번호: 703-776-3230
- 이메일: Taruni.Maganti@inova.org
-
수석 연구원:
- Jared Wilkinson, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53226
- 모집하지 않고 적극적으로
- The Medical College of Wisconsin
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.
설명
Inclusion Criteria:
-
Willing and able to provide informed consent
-
Established a new diagnosis (within 12 months) of IPF by the enrolling center.
-
Age 21 years or older, or
-
Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:
-
Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.
-
Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):
- decline in FVC % predicted (% pred) based on ≥10% relative decline
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
- decline in DLCO % pred based on≥ 10% relative decline
- worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.
-
The relative decline for FVC % predicted is calculated using the formula:
Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.
The relative decline for DLCO % predicted is calculated using the formula:
Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening
Exclusion Criteria:
- Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
- Currently listed for lung transplantation at the time of enrollment
- Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
- For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
|---|
|
Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry |
|
Subjects with a non-IPF ILD diagnosis
Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype |
|
New Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Data on natural history of IPF & non-IPF chronic fibrosing ILD
기간: End of Study (3 years after last patient will be enrolled)
|
Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
기간: End of Study (3 years after last patient will be enrolled)
|
Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD |
End of Study (3 years after last patient will be enrolled)
|
|
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
기간: End of Study (3 years after last patient will be enrolled)
|
Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL). |
End of Study (3 years after last patient will be enrolled)
|
|
Blood samples for future research.
기간: End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions. |
End of Study (3 years after last patient will be enrolled)
|
|
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
기간: End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal HRCT images for future research |
End of Study (3 years after last patient will be enrolled)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Data on management practices compared to existing guidelines.
기간: End of Study (3 years after last patient will be enrolled)
|
Compare disease-specific management practices with existing guidelines. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on center-specific practices on outcomes.
기간: End of Study (3 years after last patient will be enrolled)
|
Determine the influence of center-specific practices on patient outcomes. |
End of Study (3 years after last patient will be enrolled)
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Scott Palmer, MD, Duke Clinical Research Institute, Duke University
간행물 및 유용한 링크
일반 간행물
- Swaminathan AC, Hellkamp AS, Neely ML, Bender S, Paoletti L, White ES, Palmer SM, Whelan TPM, Dilling DF; Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry investigators. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Ann Am Thorac Soc. 2022 Jun;19(6):981-990. doi: 10.1513/AnnalsATS.202105-589OC.
- Kim HJ, Snyder LD, Neely ML, Hellkamp AS, Hotchkin DL, Morrison LD, Bender S, Leonard TB, Culver DA; IPF-PRO Registry investigators. Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry. Lung. 2022 Feb;200(1):21-29. doi: 10.1007/s00408-021-00506-x. Epub 2022 Jan 7.
- de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Culver DA, Guntupalli K, Bender S, Conoscenti CS, Snyder LD; IPF-PRO Registry Investigators. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2022 Jan 7;23(1):3. doi: 10.1186/s12931-021-01921-7.
- Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, White ES, Conoscenti CS, Strek ME; IPF-PRO Registry Investigators. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021 Sep 30;22(1):257. doi: 10.1186/s12931-021-01851-4.
- Salisbury ML, Conoscenti CS, Culver DA, Yow E, Neely ML, Bender S, Hartmann N, Palmer SM, Leonard TB; IPF-PRO Registry principal investigators as follows. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Ann Am Thorac Soc. 2020 Nov;17(11):1413-1423. doi: 10.1513/AnnalsATS.201912-880OC.
- Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA; IPF-PRO Registry Investigators. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Chest. 2020 Jun;157(6):1522-1530. doi: 10.1016/j.chest.2019.12.041. Epub 2020 Jan 29.
- O'Brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD, Culver DA, Conoscenti CS, Todd JL, Palmer SM, Leonard TB; IPF-PRO Registry investigators. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry. Chest. 2020 May;157(5):1188-1198. doi: 10.1016/j.chest.2019.11.042. Epub 2020 Jan 15.
- Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM; IPF-PRO Registry investigators. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respir Res. 2019 Oct 22;20(1):227. doi: 10.1186/s12931-019-1190-z.
- Snyder L, Neely ML, Hellkamp AS, O'Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, Kaner RJ, Palmer S, Kim HJ; IPF-PRO Registry investigators. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res. 2019 May 30;20(1):105. doi: 10.1186/s12931-019-1043-9.
- O'Brien EC, Durheim MT, Gamerman V, Garfinkel S, Anstrom KJ, Palmer SM, Conoscenti CS. Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res. 2016 Jan 11;3(1):e000108. doi: 10.1136/bmjresp-2015-000108. eCollection 2016.
- Swaminathan AC, Weber JM, Todd JL, Palmer SM, Neely ML, Whelan TP, Kim GHJ, Leonard TB, Goldin J. Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry. Respir Res. 2025 Feb 28;26(1):73. doi: 10.1186/s12931-025-03136-6.
- Oldham JM, Neely ML, Wojdyla DM, Gulati M, Li P, Patel DC, Palmer SM, Todd JL; IPF-PRO Registry Investigators. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2025 Aug;168(2):415-422. doi: 10.1016/j.chest.2025.02.018. Epub 2025 Feb 26.
- Sack C, Wojdyla DM, MacMurdo MG, Gassett A, Kaufman JD, Raghu G, Redlich CA, Li P, Olson AL, Leonard TB, Todd JL, Neely ML, Snyder LD, Gulati M; IPF-PRO Registry investigators. Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Ann Am Thorac Soc. 2025 Mar;22(3):378-386. doi: 10.1513/AnnalsATS.202404-382OC.
- Wang L, Wu P, Liu Y, Patel DC, Leonard TB, Zhao H. Clustering-aided prediction of outcomes in patients with idiopathic pulmonary fibrosis. Respir Res. 2024 Oct 23;25(1):383. doi: 10.1186/s12931-024-03015-6.
- Lobo LJ, Liu Y, Li P, Ramaswamy M, Swaminathan AC, Veeraraghavan S, Fan Y, Neely ML, Palmer SM, Olson AL; ILD-PRO Registry investigatorsdagger. Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis. BMC Pulm Med. 2024 Sep 27;24(1):468. doi: 10.1186/s12890-024-03247-8.
- Summer R, Todd JL, Neely ML, Lobo LJ, Namen A, Newby LK, Shafazand S, Suliman S, Hesslinger C, Keller S, Leonard TB, Palmer SM, Ilkayeva O, Muehlbauer MJ, Newgard CB, Roman J. Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2024 Jan 25;25(1):58. doi: 10.1186/s12931-023-02644-7.
- Neely ML, Hellkamp AS, Bender S, Todd JL, Liesching T, Luckhardt TR, Oldham JM, Raj R, White ES, Palmer SM. Lung function trajectories in patients with idiopathic pulmonary fibrosis. Respir Res. 2023 Aug 24;24(1):209. doi: 10.1186/s12931-023-02503-5.
- Ruan P, Todd JL, Zhao H, Liu Y, Vinisko R, Soellner JF, Schmid R, Kaner RJ, Luckhardt TR, Neely ML, Noth I, Porteous M, Raj R, Safdar Z, Strek ME, Hesslinger C, Palmer SM, Leonard TB, Salisbury ML. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023 May 31;24(1):141. doi: 10.1186/s12931-023-02435-0.
- Menon AA, Gansen B, Mulder H, Neely ML, Papavasileiou P, Salisbury ML, Southern BD, Hesslinger C, Leonard TB, Meissner F, Todd JL. Mass spectrometry-based peripheral blood proteomics for biomarker discovery in idiopathic pulmonary fibrosis. Respir Res. 2025 Oct 22;26(1):294. doi: 10.1186/s12931-025-03377-5.
- Shetty S, Swaminathan AC, Li P, Neely ML, Olson AL, Snyder LD; ILD-PRO Registry investigators. Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry. Lung. 2026 May 27;204(1):32. doi: 10.1007/s00408-026-00895-x.
- Swaminathan AC, Mulder H, Neely ML, Schmid R, Belperio JA, Patel NM, Palmer SM, Todd JL. Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis. Respir Res. 2026 Mar 25;27(1):196. doi: 10.1186/s12931-026-03641-2.
- Neely ML, Todd JL, Snyder LD, Li P, Olson AL; IPF-PRO Registry Investigators *. Trajectories of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. CHEST Pulm. 2024 Dec 27;3(4):100133. doi: 10.1016/j.chpulm.2024.100133. eCollection 2025 Dec.
- MacMurdo MG, Wojdyla DM, Gassett A, Kaufman JD, Raghu G, Redlich CA, Patel DC, Neely ML, Snyder LD, Gulati M, Sack C; IPF-PRO Registry investigators. Short-term air pollution exposure and hospitalizations in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Ann Am Thorac Soc. 2026 Sep 12:aaoag285. doi: 10.1093/annalsats/aaoag285. Online ahead of print.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- Pro00046131
- 1199.174 (기타 식별자: DCRI)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .